Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib in Relapsed or Refractory Multiple Myeloma
NCT01085214Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Mar 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selumetinib in multiple myeloma (MM), sponsored by National Cancer Institute. Started Mar 2010; status: completed.
02
Drugs
selumetinib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01085214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01085214.